Trials that use: Interim analysis / alpha spending
New to this method? Read the tutorial →
11,819 results
- PASSPORTIndependent statistical analysis of Study of BIIB092 in Participants With Progressive Supranuclear Palsy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03068468).
- PATCHIndependent statistical analysis of Feasibility Study of the µCor Heart Failure and Arrhythmia Management System (PATCH): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- PATCHIndependent statistical analysis of Pre-hospital Advanced Therapies for Control of Hemorrhage - Pelvis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02855060).
- PATCHIndependent statistical analysis of The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04329923).
- PATHIndependent statistical analysis of PATH Partnering to Achieve Tobacco-free Health: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01533974).
- Pathogenesis of Stress-Induced Cardiomyopathy by I-123 MIBG: Complete Statistical AnalysisIndependent statistical analysis of Pathogenesis of Stress-Induced Cardiomyopathy by I-123 MIBG: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01432626).
- Patient Centered Postpartum Contraception App: Complete Statistical AnalysisIndependent statistical analysis of Patient Centered Postpartum Contraception App: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03402217).
- Patient Experience Study of Deoxycholic Acid Injection: Complete Statistical AnalysisIndependent statistical analysis of Patient Experience Study of Deoxycholic Acid Injection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02007434).
- Patient Perception of Visual Quality and Function: Complete Statistical AnalysisIndependent statistical analysis of Patient Perception of Visual Quality and Function: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02146599).
- Patient Portal Flu Vaccine Reminders (5): Complete Statistical AnalysisIndependent statistical analysis of Patient Portal Flu Vaccine Reminders (5): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05525494).
- Patient Reported Satisfaction With Contoura LASIK Utilizing the Phorcides Analytic Software: Complete Statistical AnalysisIndependent statistical analysis of Patient Reported Satisfaction With Contoura LASIK Utilizing the Phorcides Analytic Software: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Patient-Directed Antimicrobial Duration in Acute Uncomplicated Pyelonephritis: Complete Statistical AnalysisIndependent statistical analysis of Patient-Directed Antimicrobial Duration in Acute Uncomplicated Pyelonephritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06127160).
- Patient-Reported Outcomes Measurement Information System Integration Into Rheumatology Clinical Practice: Complete Statistical AnalysisIndependent statistical analysis of Patient-Reported Outcomes Measurement Information System Integration Into Rheumatology Clinical Practice: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05026853).
- Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Patients With Geographic Atrophy and Their Patient Journey in the United States (US): Complete Statistical AnalysisIndependent statistical analysis of Patients With Geographic Atrophy and Their Patient Journey in the United States (US): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy: Complete Statistical AnalysisIndependent statistical analysis of Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Paxerol™ for Treatment of Nocturia – A Phase II Placebo-Controlled Trial: Complete Statistical AnalysisIndependent statistical analysis of Paxerol™ for Treatment of Nocturia - A Phase II Placebo-Controlled Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size…
- Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00625846).
- Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pazopanib in Treating Patients With Metastatic Urothelial Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pazopanib in Treating Patients With Metastatic Urothelial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00471536).
- Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC): Complete Statistical AnalysisIndependent statistical analysis of Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01392183).
- PBroCIndependent statistical analysis of Chemoprevention of Prostate Cancer, HDAC Inhibition and DNA Methylation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01265953).
- PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding: Complete Statistical AnalysisIndependent statistical analysis of PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02557672).
- PCIIndependent statistical analysis of A Clinical Trial to Demonstrate the Efficacy of Cangrelor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00305162).
- PCMH-KDIndependent statistical analysis of Bringing Care to Patients: Patient-Centered Medical Home for Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02270515).
- PCN1Independent statistical analysis of Patient Centered-Rehabilitation ver111090.1: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03034954).
- PCOSIndependent statistical analysis of Effects of Pioglitazone on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome (PCOS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- PCR PS TKAIndependent statistical analysis of Knee Kinematics for Subjects With Zimmer-Biomet Posterior Cruciate Retaining or Posterior Stabilizing Total Knee Arthroplasty: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung: Complete Statistical AnalysisIndependent statistical analysis of PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- PCTDMRTTIndependent statistical analysis of Placebo Controlled Trial of Dextromethorphan in Rett Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01520363).
- PCV13 Effectiveness Study Against Hospitalised VT Pneumococcal CAP in Adults 60 Years and Older: Complete Statistical AnalysisIndependent statistical analysis of PCV13 Effectiveness Study Against Hospitalised VT Pneumococcal CAP in Adults 60 Years and Older: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- PDIndependent statistical analysis of Vancomycin Plus Moxifloxacin Versus Vancomycin Plus Ceftazidime for the Treatment of Peritoneal Dialysis (PD)-Related Peritonitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- PDIndependent statistical analysis of Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04928287).
- PD0332991Independent statistical analysis of A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- PDOP_TLRIndependent statistical analysis of Percutaneous Diskectomy SpineJet x Open Microdiskectomy in Treatment of Lumbar Radiculopathy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- PDT/PDLIndependent statistical analysis of Combined Photodynamic and Pulsed Dye Laser Treatment of Port Wine Stains: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- PEACE IIIndependent statistical analysis of Positive Psychology to Improve Healthy Behaviors After an Acute Coronary Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors: Complete Statistical AnalysisIndependent statistical analysis of PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors: primary endpoint…
- PeanutFlourIndependent statistical analysis of Peanut Oral Immunotherapy in Children With Peanut Allergy (Peanut Flour): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02203799).
- PEARL 3 ExtIndependent statistical analysis of Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- PEARL-HFIndependent statistical analysis of Evaluation of Patiromer in Heart Failure Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00868439).
- PEARL-IIndependent statistical analysis of A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection: primary endpoint results,…
- PEARL-IVIndependent statistical analysis of A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- PEARLIIIndependent statistical analysis of PGL4001 Versus GnRH-agonist in Uterine Myomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00740831).
- PEARLSIndependent statistical analysis of Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- PECEPIndependent statistical analysis of Prevention of Preterm Birth Using Cervical Pessary in Pregnant Women With Short Cervix: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Pecto-Intercostal Fascial Plane Block Study: Complete Statistical AnalysisIndependent statistical analysis of Pecto-Intercostal Fascial Plane Block Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04928339).